FRIDAY, April 27 (HealthDay News) -- A novel lipocalin dog allergen has been identified in nearly 40 percent of dog-sensitized individuals, which cross-reacts with lipocalins from cat and horse, according to a study published online April 20 in Allergy.
Ola B. Nilsson, from the Karolinska Institutet in Stockholm, and colleagues cloned and characterized a novel dog allergen and assessed its role in cross-sensitization between dog, cat, and horse. The allergen corresponding to the gene encoding Can f 6, which was amplified from dog skin and bladder complementary DNA libraries, was produced, purified, and evaluated.
The researchers found that 38 percent of dog-sensitized subjects had immunoglobulin E antibodies to Can f 6. There were sequence similarities between the lipocalin allergens Can f 6, Fel d 4 from cat, and Equ c 1 from horse. Competitive enzyme-linked immunosorbent assay demonstrated cross-reactivity between these allergens. In dog-allergic patients, the biological relevance of Can f 6 was confirmed with the basophil activation test.
"Can f 6 is a new lipocalin dog allergen that cross-reacts with lipocalins from horse and cat. Can f 6 and homologous allergens may contribute to multisensitization and symptoms in individuals allergic to mammals," the authors write.
Copyright © 2012 HealthDay. All rights reserved.
|Previous: Cancer Worry Linked to Continued Symptom Burden||Next: AAN: Migraine Prevalence Up in Celiac Disease, IBD Patients|
Reader comments on this article are listed below. Review our comments policy.